At the Mobile Congress in Barcelona last week, shoemaker Puma launched a new Puma Phone to appeal to the on-the-go, healthy lifestyle of their target consumers.

Hmmm. A branded “lifestyle” phone?
Think the Viagra phone is far away?
While it’s easy to say it will “never happen in pharma,” the rapid changes in mobile adoption around the world suggest that, perhaps, anything could happen. As the technology gets less expensive, global mobile adoption has exploded, blurring the roles of function, entertainment, brand and marketing.
If 5 years ago someone had predicted that the bookseller Amazon would one day have its own line of computers it would have seemed far fetched, right? But now there’s Kindle: a branded product (software) on an emerging technology (tablet).
The good news for pharma: sometimes being later to market is better.
Technology companies know they learn as much from going through the launch of a new technology (tablet, mobile, etc.) as they did developing the product in the first place. That knowledge becomes “the bigger part” of theie intellectual property (IP). The experience of doing it first, or early, becomes the competitive advantage, not just the software, or device. Early adopters have experienced more earlier, so they figure out how to avoid the mistakes for version 2.0 (in software).
For pharma it will be the second version of their tablet application, or mobile device app that translates to success, because the IP gathered from the first version will have taught those brand managers what works, what doesn’t and (drum roll) why it worked.

